1
|
Shahinian JH, Fuellgraf H, Tholen S, Mastroianni J, Knopf JD, Kuehs M, Mayer B, Schlimpert M, Kulemann B, Kuesters S, Hoeppner J, Wellner UF, Werner M, Hopt UT, Zeiser R, Bronsert P, Schilling O. Pregnancy Specific β-1 Glycoprotein 1 is Expressed in Pancreatic Ductal Adenocarcinoma and its Subcellular Localization Correlates with Overall Survival. J Cancer 2016; 7:2018-2027. [PMID: 27877217 PMCID: PMC5118665 DOI: 10.7150/jca.15864] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2016] [Accepted: 09/18/2016] [Indexed: 12/14/2022] Open
Abstract
Proteins of the pregnancy specific β-1 glycoprotein (PSG) family are renowned for their elevated expression during pregnancy. Only few reports have investigated their expression in adenocarcinomas. We studied the expression of PSG1 in pancreatic adenocarcinoma (PDAC). In a cohort of 104 patient samples, immunohistochemical analysis determined PSG1 expression in every specimen. PSG1 was found at apical and cytoplasmic localization or solely at cytoplasmic localization, with the latter case being correlated to shortened median survival (25 vs 11 months, logrank p-value < 0.001). At the same time, enzyme linked immunosorbent assay (ELISA) did not detect elevated PSG1 levels in the plasma of PDAC patients as opposed to the plasma of healthy, non-pregnant control individuals. We also probed the impact of PSG1 expression in a murine tumor model system, using subcutaneous injection of Colo-26 cells into immunocompetent BALB/c mice. Here, tumor growth was not affected by the expression of human PSG1. Our study reaffirms interest into the tumor-contextual biology of PSG proteins.
Collapse
Affiliation(s)
- Jasmin H Shahinian
- Division of Cardiac Surgery, University Hospital Basel, Basel, Switzerland
| | - Hannah Fuellgraf
- Institute of Surgical Pathology, University Medical Center Freiburg, Germany
| | - Stefan Tholen
- Institute of Molecular Medicine and Cell Research, University of Freiburg, Germany
| | - Justin Mastroianni
- Department of Hematology and Oncology, University Medical Center Freiburg, Germany
| | - Julia Daniela Knopf
- Institute of Molecular Medicine and Cell Research, University of Freiburg, Germany;; present address: Zentrum für Molekulare Biologie der Universität Heidelberg (ZMBH), DKFZ-ZMBH Allianz, Im Neuenheimer Feld 282, 69120 Heidelberg, Germany
| | - Markus Kuehs
- Institute of Surgical Pathology, University Medical Center Freiburg, Germany;; Comprehensive Cancer Center Freiburg, Germany
| | - Bettina Mayer
- Institute of Molecular Medicine and Cell Research, University of Freiburg, Germany
| | - Manuel Schlimpert
- Institute of Molecular Medicine and Cell Research, University of Freiburg, Germany
| | - Birte Kulemann
- Clinic for General and Visceral Surgery, University Medical Center Freiburg, Germany
| | - Simon Kuesters
- Clinic for General and Visceral Surgery, University Medical Center Freiburg, Germany
| | - Jens Hoeppner
- Clinic for General and Visceral Surgery, University Medical Center Freiburg, Germany;; Comprehensive Cancer Center Freiburg, Germany
| | - Ulrich F Wellner
- Clinic for Surgery, University Clinic Schleswig-Holstein Campus Lübeck, Germany
| | - Martin Werner
- Institute of Surgical Pathology, University Medical Center Freiburg, Germany;; Comprehensive Cancer Center Freiburg, Germany;; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, German
| | - Ulrich T Hopt
- Clinic for General and Visceral Surgery, University Medical Center Freiburg, Germany
| | - Robert Zeiser
- Department of Hematology and Oncology, University Medical Center Freiburg, Germany;; BIOSS Centre for Biological Signaling Studies, University of Freiburg, D-79104 Freiburg, Germany
| | - Peter Bronsert
- Institute of Surgical Pathology, University Medical Center Freiburg, Germany;; Comprehensive Cancer Center Freiburg, Germany;; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, German
| | - Oliver Schilling
- Institute of Molecular Medicine and Cell Research, University of Freiburg, Germany;; BIOSS Centre for Biological Signaling Studies, University of Freiburg, D-79104 Freiburg, Germany;; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, German
| |
Collapse
|